Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

Circadian Disruption and Diet-Induced Obesity Synergize to Promote Development of β-Cell Failure and Diabetes in Male Rats
Qian, Jingyi , Yeh, Bonnie, Rakshit, Kuntol, Colwell, Christopher S. , Matveyenko, Aleksey V.

Endocrinology | September 8, 2015 | Volume: 156 | Issue: 12 | Pages: 4426-4436

10.1210/en.2015-1516 | PMID 26348474 Get It

There are clear epidemiological associations between circadian disruption, obesity, and pathogenesis of type 2 diabetes. The mechanisms driving these associations are unclear. In the current study, we hypothesized that continuous exposure to constant light (LL) compromises pancreatic β-cell functional and morphological adaption to diet-induced obesity leading to development of type 2 diabetes. To address this hypothesis, we studied wild type Sprague Dawley as well as Period-1 luciferase reporter transgenic rats (Per1-Luc) for 10 weeks under standard light-dark cycle (LD) or LL with concomitant ad libitum access to either standard chow or 60% high-fat diet (HFD). Exposure to HFD led to a comparable increase in food intake, body weight, and adiposity in both LD- and LL-treated rats. However, LL rats displayed profound loss of behavioral circadian rhythms as well as disrupted pancreatic islet clock function characterized by the impairment in the amplitude and the phase islet clock oscillations. Under LD cycle, HFD did not adversely alter diurnal glycemia, diurnal insulinemia, β-cell secretory function as well as β-cell survival, indicating successful adaptation to increased metabolic demand. In contrast, concomitant exposure to LL and HFD resulted in development of hyperglycemia characterized by loss of diurnal changes in insulin secretion, compromised β-cell function, and induction of β-cell apoptosis. This study suggests that circadian disruption and diet-induced obesity synergize to promote development of β-cell failure, likely mediated as a consequence of impaired islet clock function.
Mosaic Pattern of Lung Attenuation on Chest CT in Patients with Pulmonary Hypertension
Lee, Augustine S. , Ussavarungsi, Kamonpun , Burger, Charles D.

Diseases | September 8, 2015 | Volume: 3 | Issue: 3 | Pages: 205-212

10.3390/diseases3030205 | PMID 28943620 Get It

A mosaic pattern of lung attenuation on chest computed tomography (CT) may be due to various etiologies. There is limited published data on CT results when used to evaluate pulmonary hypertension (PH). We retrospectively studied the frequency of mosaic pattern in patients with PH and the cause of the PH by diagnostic group, as well as the correlation between the mosaic pattern and the following: demographics, severity of the PH, main pulmonary artery (PA) size, PA/aorta (PA/Ao) ratio, pulmonary function tests (PFT), and ventilation perfusion scan results. Overall, 18% of the cohort had CT mosaic pattern (34/189). Mosaic pattern was present in 17/113 (15%) in Group 1 pulmonary arterial hypertension, 5/13 (28%) in Group 2 pulmonary venous hypertension and 8/50 (16%) in Group 3 PH. Conversely, Group 4 chronic thromboembolic PH was more prevalent in 4/8 (50%). Main PA size, PA/Ao ratio, and segmental perfusion defect were positively associated with mosaic pattern. In contrast, factors such as age, gender, body mass index, functional class, hemodynamic data, and PFT values were not associated with mosaic pattern. Mosaic pattern is not specific as an isolated finding for distinguishing the subtype of PH.
The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy
Shah, Sanaya, Lacy, Brian E. , DiBaise, John K. , Vela, Marcelo F. , Lacy, Brian E. , Crowell, Michael D.

Alimentary Pharmacology & Therapeutics | September 8, 2015 | Volume: 42 | Issue: 9 | Pages: 1093-1100

10.1111/apt.13394 | PMID 26345151 Get It

SummaryBackgroundObesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro‐oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs).AimTo evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms.MethodsAcid exposure time profiles collected from adult patients using wireless pH‐metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods.ResultsThe study group comprised 968 patients with 336 (34.7%) studied on a PPI and 632 (65.3%) studied off PPI therapy. AET (total greater than 5.3%) was found more frequently in the overweight (67%) and obese classes (74–80%) compared to those who were normal weight (40%) while off acid‐suppressing medications (P < 0.001). No significant differences were found between these groups when studied on acid‐suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily.ConclusionsThis is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight‐based groups when taking a once or twice‐daily PPI.
Relative Quantification and Higher-Order Modeling of the Plasma Glycan Cancer Burden Ratio in Ovarian Cancer Case-Control Samples
Hecht, Elizabeth S. , Scholl, Elizabeth H. , Walker, Stephan , Taylor, Amber D., Cliby, William A. , Motsinger‐Reif, Alison A. , Muddiman, David C.

Journal of Proteome Research | September 8, 2015 | Volume: 14 | Issue: 10 | Pages: 4394-4401

10.1021/acs.jproteome.5b00703 | PMID 26347193 Get It

To clamp or not to clamp? Long‐term functional outcomes for elective off‐clamp laparoscopic partial nephrectomy
Shah, Paras , George, Arvin K. , Moreira, Daniel M. , Alom, Manaf, Okhunov, Zhamshid , Salami, Simpa S. , Waingankar, Nikhil , Schwartz, Michael J. , Vira, Manish , Richstone, Lee, Kavoussi, Louis R., Salami, Simpa S

BJU International | September 8, 2015 | Volume: 117 | Issue: 2 | Pages: 293-299

10.1111/bju.13309 | PMID 26348366 Get It

Objective To evaluate whether elective off‐clamp laparoscopic partial nephrectomy ( LPN ) affords long‐term renal functional benefit compared with the on‐clamp approach. Patients and Methods This is a retrospective review of patients who underwent elective LPN between 2006 and 2011. Patients were followed longitudinally for up to 5 years. In all, 315 patients with radiographic evidence of a solitary renal mass and normal‐appearing contralateral kidney underwent elective LPN ; 209 were performed on‐clamp vs 106 off‐clamp. One patient who required conversion from LPN to open PN was excluded from the study. Additionally, four patients in the on‐clamp cohort who underwent subsequent radical nephrectomy for local‐regional recurrence were excluded from longitudinal functional evaluation after their procedure. The primary objective was to evaluate differences in postoperative estimated glomerular filtration rate ( eGFR ) between hilar clamping groups. Subgroup analyses were performed for patients with clamp times >30 min and those with baseline renal insufficiency ( eGFR <60 mL/min/1.73m 2 ). Risk of developing worsened or new‐onset renal insufficiency was also compared. Results The mean preoperative eGFR was similar between the on‐clamp and off‐clamp cohorts (80.7 vs 84.1 mL/min/1.73m 2 , P > 0.05). Univariable and multivariable analyses did not show significant differences in postoperative eGFR between both groups among all‐comers, those with clamp times >30 min, and patients with baseline renal insufficiency. Risk of chronic kidney disease was not diminished by the off‐clamp approach with up to 5 years of follow‐up. Conclusions Progressive recovery of renal function after hilar clamping in the elective setting eclipses short‐term functional benefit achieved with off‐clamp LPN by 6 months; there was no significant difference in eGFR or the percentage incidence of chronic kidney disease between the on‐clamp and off‐clamp cohorts with up to 5 years follow‐up. As such, eliminating transient ischaemia during elective LPN does not confer clinical benefit.
Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER‐2 positive patients presenting with clinically node‐negative disease
Al‐Hilli, Zahraa , Heins, Courtney N., Hoskin, Tanya L. , Hieken, Tina J. , Boughey, Judy C.

Journal of Surgical Oncology | September 8, 2015 | Volume: 112 | Issue: 5 | Pages: 453-457

10.1002/jso.24034 | PMID 26345596 Get It

ObjectivesWe investigated the impact of neoadjuvant chemotherapy (NAC) on axillary disease burden in clinically node‐negative (cN0) HER‐2 positive breast cancer patients.MethodsWe studied 215 cN0 patients with HER‐2 positive tumors. Multivariable logistic regression was used to compare NAC versus primary surgery (PS) with respect to outcome of pathologic nodal disease.ResultsOf 215 patients, 42 (20%) received NAC. NAC use correlated with higher clinical T stage (P < 0.0001) and younger age (P = 0.03) with no difference in ER/PR status or tumor grade. Despite higher clinical T stage in the NAC group, rate of pathologic positive axillary nodes was non‐significantly lower (NAC 5/42 = 11.9%, PS 27/173 = 15.6%, P = 0.54). In multivariable analysis, after adjustment for confounders including clinical T stage, age, and multifocal/multicentric disease, NAC showed significant reduction in odds of pathologic nodal disease (OR 0.26, 95%CI:0.06–0.90, P = 0.03). Further, among those with pathologic nodal disease, the number of positive nodes was lower after NAC (adjusted P = 0.03). Extranodal extension was present in 8/27 (30%) PS patients vs. 1/5 (20%) of the NAC patients (adjusted P = 0.36).ConclusionNAC in cN0 HER‐2 positive breast cancers reduces the rate of pathologic node‐positive disease at operation and nodal disease burden and may decrease the need for axillary node dissection. J. Surg. Oncol. 2015; 112:453–457. © 2015 Wiley Periodicals, Inc.
Biomarkers for bile acid diarrhoea in functional bowel disorder with diarrhoea: a systematic review and meta-analysis
Valentin, Nelson, Camilleri, Michael , Altayar, Osama , Vijayvargiya, Priya , Nelson, Alfred D. , Murad, M. Hassan , Acosta, Andrés , Murad, M Hassan , Altayar, Osama

Gut | September 7, 2015 | Volume: 65 | Issue: 12 | Pages: 1951-1959

10.1136/gutjnl-2015-309889 | PMID 26347530 Get It

There is no universally available laboratory test to diagnose bile acid diarrhoea (BAD). Objective To conduct a systematic review and meta-analysis to identify a biomarker for idiopathic BAD in patients with functional bowel disorder (FBD) with diarrhoea. Design We searched multiple databases through 15 May 2015. Data were only available to estimate the diagnostic yield of each test (the prevalence of a positive test). Estimates were pooled across studies using the random effects model. Results We included 36 studies, enrolling 5028 patients (24 using 75 selenium homotaurocholic acid test ( 75 SeHCAT) retention of <10%, 6 using fasting serum C4, 3 using fasting serum fibroblast growth factor 19 (FGF19) and 2 based on total faecal bile acid (BA) excretion over 48 h). The diagnostic yields (and 95% CI) of abnormal tests were: 0.308 (0.247 to 0.377) for 75 SeHCAT retention (<10%), 0.171 (0.134 to 0.217) for serum C4, 0.248 (0.147 to 0.385) for serum FGF19 and 0.255 (0.071 to 0.606) for total faecal BA excretion over 48 h. The majority of the analyses were associated with substantial heterogeneity. Performance characteristics relative to a gold standard test could not be estimated. Conclusions Overall, the test with the highest diagnostic yield conducted in the largest number of studies was 75 SeHCAT retention, which is not widely available in many countries outside Europe and Canada. Using different diagnostic tests, 25% (average) of patients with lower FBD with diarrhoea has evidence of idiopathic BAD. These tests serve to identify idiopathic BAD among patients with FBD with diarrhoea. Further studies are required to appraise the performance characteristics of tests for idiopathic BAD.
Association Between Atrial Fibrillation and Costs After Myocardial Infarction: A Community Study
Roger, Véronique L. , Mills, Roger M. , Weston, Susan A., Anderson, Stephanie S., Chamberlain, Alanna M. , Borah, Bijan J. , Mills, Roger M , Chamberlain, Alanna M

Clinical Cardiology | September 7, 2015 | Volume: 38 | Issue: 9 | Pages: 548-554

10.1002/clc.22448 | PMID 26418757 Get It

ABSTRACTBackgroundThe authors sought to estimate incremental economic impact of atrial fibrillation (AF) and the timing of its onset in myocardial infarction (MI) patients.HypothesisConcurrent AF and its timing are associated with higher costs in MI patients.MethodsThis retrospective cohort study included incident MI patients from Olmsted County, Minnesota, treated between November 1, 2002, and December 31, 2010. We compared inflation‐adjusted standardized costs accumulated between incident MI and end of follow‐up among 3 groups by AF status and timing: no AF, new‐onset AF (within 30 days after index MI), and prior AF. Multivariate adjustment of median costs accounted for right‐censoring in costs.ResultsThe final study cohort had 1389 patients, with 989 in no AF, 163 in new‐onset AF, and 237 in prior AF categories. Median follow‐up times were 3.98, 3.23, and 2.55 years, respectively. Mean age at index was 67 years, with significantly younger patients in the no AF group (64 years vs 76 and 77 years, respectively; P < 0.001). New‐onset and prior AF patients had more comorbid conditions (hypertension, heart failure, and chronic obstructive pulmonary disease). After accounting for differences in baseline characteristics, we found adjusted median (95% confidence interval) costs of $73 000 ($69 000‐$76 000) for no AF; $85 000 ($81 000‐$89 000) for new‐onset AF; and $97 000 ($94 000‐$100 000) for prior AF. Inpatient costs composed the largest share of total median costs (no AF, 82%; new‐onset AF, 84%; prior AF, 83%).ConclusionsAtrial fibrillation frequently coexists with MI and imposes incremental costs, mainly attributable to inpatient care. Timing of AF matters, as prior AF was found to be associated with higher costs than new‐onset AF.
Mitotic Inheritance of mRNA Facilitates Translational Activation of the Osteogenic‐Lineage Commitment Factor Runx2 in Progeny of Osteoblastic Cells
Varela, Nelson , Aránguiz, Alejandra, Lizama, Carlos O. , Sepúlveda, Hugo , Antonelli, Marcelo , Thaler, Roman , Moreno, Ricardo D. , Montecino, Martı́n , Stein, Gary S., Wijnen, André J. van , Galindo, Mario , van Wijnen, Andre J, van Wijnen, Andre J

Journal of Cellular Physiology | September 7, 2015 | Volume: 231 | Issue: 5 | Pages: 1001-1014

10.1002/jcp.25188 | PMID 26381402 Get It

Epigenetic mechanisms mediate the acquisition of specialized cellular phenotypes during tissue development, maintenance and repair. When phenotype‐committed cells transit through mitosis, chromosomal condensation counteracts epigenetic activation of gene expression. Subsequent post‐mitotic re‐activation of transcription depends on epigenetic DNA and histone modifications, as well as other architecturally bound proteins that “bookmark” the genome. Osteogenic lineage commitment, differentiation and progenitor proliferation require the bone‐related runt‐related transcription factor Runx2. Here, we characterized a non‐genomic mRNA mediated mechanism by which osteoblast precursors retain their phenotype during self‐renewal. We show that osteoblasts produce maximal levels of Runx2 mRNA, but not protein, prior to mitotic cell division. Runx2 mRNA partitions symmetrically between daughter cells in a non‐chromosomal tubulin‐containing compartment. Subsequently, transcription‐independent de novo synthesis of Runx2 protein in early G1 phase results in increased functional interactions of Runx2 with a representative osteoblast‐specific target gene (osteocalcin/BGLAP2) in chromatin. Somatic transmission of Runx2 mRNAs in osteoblasts and osteosarcoma cells represents a versatile mechanism for translational rather than transcriptional induction of this principal gene regulator to maintain osteoblast phenotype identity after mitosis. J. Cell. Physiol. 231: 1001–1014, 2016. © 2015 Wiley Periodicals, Inc.
Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era
Diefenbach, Catherine , Li, Hailun , Fisher, Richard I., Bartlett, Nancy L. , Crump, Michael , Gascoyne, Randy D. , Wagner, Henry, Stiff, Patrick J. , Cheson, Bruce D. , Stewart, Douglas A. , Friedberg, Jonathan W. , Blum, Kristie A. , Tuscano, Joseph M. , Hoppe, Richard T. , Horning, Sandra J., Advani, Ranjana H. , Hong, Fangxin , Gordon, Leo I. , Kahl, Brad S. , Habermann, Thomas M. , Bartlett, Nancy L , Advani, Ranjana H , Hoppe, Richard T , Diefenbach, Catherine S

British Journal of Haematology | September 7, 2015 | Volume: 171 | Issue: 4 | Pages: 530-538

10.1111/bjh.13634 | PMID 26343802 Get It

SummaryThe International Prognostic Score (IPS‐7) is the most commonly used risk stratification tool for advanced Hodgkin lymphoma (HL), however recent studies suggest the IPS‐7 is less discriminating due to improved outcomes with contemporary therapy. We evaluated the seven variables for IPS‐7 recorded at study entry for 854 patients enrolled on Eastern Cooperative Oncology Group 2496 trial. Univariate and multivariate Cox models were used to assess their prognostic ability for freedom from progression (FFP) and overall survival (OS). The IPS‐7 remained prognostic however its prognostic range has narrowed. On multivariate analysis, two factors (age, stage) remained significant for FFP and three factors (age, stage, haemoglobin level) for OS. An alternative prognostic index, the IPS‐3, was constructed using age, stage and haemoglobin level, which provided four distinct risk groups [FFP (P = 0·0001) and OS (P < 0·0001)]. IPS‐3 outperformed the IPS‐7 on risk prediction for both FFP and OS by model fit and discrimination criteria. Using reclassification calibration, 18% of IPS‐7 low risk patients were re‐classified as intermediate risk and 13% of IPS‐7 intermediate risk patients as low risk. For patients with advanced HL, the IPS‐3 may provide a simpler and more accurate framework for risk assessment in the modern era. Validation of these findings in other large data sets is planned.